BioNTech Starts Dosing In Mid-Stage Colorectal Cancer Immunotherapy Trial

  • BioNTech SE BNTX has dosed the first patient with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in Phase 2 clinical trial. 
  • The trial plans to enroll about 200 patients.
  • The open-label Phase 2 trial is investigating BNT122 in stage 2/3 colorectal cancer patients after surgical resection of their tumor and completion of adjuvant chemotherapy. 
  • The trial will investigate the efficacy of autogene cevumeran as a single agent compared to the standard of care. 
  • The primary endpoint for the study is disease-free survival (DFS). Secondary objectives include relapse-free survival (RFS), overall survival (OS), and safety.
  • Autogene cevumeran is individualized neoantigen-specific immunotherapy (iNeST) and the lead candidate from BioNTech's mRNA-based cancer vaccine platform. 
  • Since 2016, BioNTech has advanced mRNA-based cancer vaccines targeting neoantigens in collaboration with Genentech, a unit of Roche Holdings AG RHHBY.
  • BioNTech will sponsor and operationalize the colorectal cancer Phase 2 trial. 
  • Joint development with Genentech of autogene cevumeran in other trials with Genentech will continue. 
  • Price Action: BNTX stock is down 7.01% at $253.85 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefscolorectal cancerPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!